Yie-sung Seo

1 Introduction Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive variant, MASH (formerly NASH), have been redefined to highlight the critical significance of metabolic dysfunction in fatty liver disease [1]. MASH is marked by hepatic steatosis accompanied by inflammation and hepatocellular damage, potentially advancing to fibrosis, cirrhosis and hepatocellular carcinoma [2, 3].